Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$4.84 USD
+0.18 (3.86%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $4.83 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CAPR 4.84 +0.18(3.86%)
Will CAPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
Other News for CAPR
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
Capricor announces three-year safety, efficacy results from HOPE-2 OLE study
CORRECTION: Capricor Therapeutics
Capricor gains FDA pre-BLA meeting on deramiocel for Duchenne muscular dystrophy
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy